Xinhua News Agency, Washington, October 2 (Reporter Tan Jingjing) U.S. President Trump said on social media early on the 2nd that he and his wife Melania had tested positive for the new crown virus.
Later that day, White House doctor Sean Conley said that Trump received "antibody cocktail therapy."
Conley said in a statement that after Trump was diagnosed with the new crown, as a preventive measure, Trump received polyclonal antibody treatment from Regeneron Pharmaceuticals, a single dose of 8 grams.
In addition, he also took zinc, vitamin D, famotidine, melatonin and aspirin.
What is the principle of this antibody cocktail therapy?
How's the effect?
According to the official website of Regeneron Pharmaceuticals, this therapy called REGN-COV2 is composed of two monoclonal antibodies REGN10933 and REGN10987, which are designed to block the process of new coronavirus infecting the human body.
These two antibodies bind to the key receptor of the new coronavirus spike protein in a non-competitive manner, and the combination of the two can reduce the ability of the mutant virus to evade single antibody treatment.
On September 29, Regeneron Pharmaceuticals announced the early results of clinical trials of the therapy.
The results show that this therapy reduces the viral load and shortens the time it takes for non-hospital patients with new coronary disease to relieve symptoms.
For patients who have not produced an effective immune response to the new coronavirus, the effect of this therapy is most obvious.
Regeneron Pharmaceuticals initially recruited 275 non-hospital patients with COVID-19 to participate in the trial.
These patients were randomly divided into 3 groups and received a single intravenous injection of 8 grams (high dose) of antibody cocktail therapy, a single intravenous injection of 2.4 grams (low dose) of the therapy, and placebo.
Before treatment, the researchers performed relevant serum tests on the patients to determine whether they had produced antibodies themselves.
The test results showed that the median time to symptom relief for seronegative patients who received placebo was 13 days, for patients who received high-dose therapy for 8 days, and for patients who received low-dose therapy for 6 days.
Both doses of antibody cocktail therapy were well tolerated.
Regeneron Pharmaceuticals said that in addition to clinical trials on non-inpatient patients with the new crown, its researchers are studying the effects of antibody cocktail therapy in hospitalized patients.